We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+6.68%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$596M
Cap. Flow
+$655M
Cap. Flow %
30.37%
Top 10 Hldgs %
48.34%
Holding
102
New
45
Increased
15
Reduced
8
Closed
34

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.9M
2
BIIB icon
Biogen
BIIB
+$87.9M
3
AKBA icon
Akebia Therapeutics
AKBA
+$64.3M
4
AVTR icon
Avantor
AVTR
+$61.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$48.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.4M
2
IMMU
Immunomedics Inc
IMMU
+$67.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57M
4
HOLX
Hologic
HOLX
+$46.6M
5
EXEL icon
Exelixis
EXEL
+$44.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.12%
2 Technology 1.7%
3 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
76
DELISTED
Esperion Therapeutics
ESPR
– –
-559,700
Closed -$28.7M
HOLX
77
DELISTED
Hologic
HOLX
– –
-817,200
Closed -$46.6M
LEGN icon
78
Legend Biotech
LEGN
$3.65B
– –
-100,000
Closed -$4.26M
MCK icon
79
McKesson
MCK
$104B
– –
-128,000
Closed -$19.6M
NBIX icon
80
Neurocrine Biosciences
NBIX
$18.2B
– –
-185,100
Closed -$22.6M
NTLA icon
81
Intellia Therapeutics
NTLA
$1.51B
– –
-418,178
Closed -$8.79M
RCUS icon
82
Arcus Biosciences
RCUS
$3.33B
– –
-589,000
Closed -$14.6M
REGN icon
83
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-132,100
Closed -$82.4M
RNAM
84
DELISTED
Avidity Biosciences
RNAM
– –
-234,814
Closed -$6.64M
RPRX icon
85
Royalty Pharma
RPRX
$26.2B
– –
-200,000
Closed -$9.71M
TVTX icon
86
Travere Therapeutics
TVTX
$5.17B
– –
-250,000
Closed -$5.1M
VIR icon
87
Vir Biotechnology
VIR
$1.46B
– –
-620,600
Closed -$25.4M
VSTM icon
88
Verastem
VSTM
$528M
– –
-367,916
Closed -$7.59M
DCPH
89
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-156,266
Closed -$9.33M
FUSN
90
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-164,554
Closed -$2.88M
SYNH
91
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-366,500
Closed -$21.3M
SURF
92
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-1,478,699
Closed -$9.7M
ONEM
93
DELISTED
1Life Healthcare
ONEM
– –
-200,000
Closed -$7.26M
BIOR
94
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
– –
-955
Closed -$2.15M
AKUS
95
DELISTED
Akouos Inc
AKUS
– –
-315,000
Closed -$7.09M
CCXI
96
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-645,800
Closed -$37.2M
ALXN
97
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-507,700
Closed -$57M
PRVL
98
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-1,028,800
Closed -$15.3M
IMMU
99
DELISTED
Immunomedics Inc
IMMU
– –
-1,911,300
Closed -$67.7M
MNTA
100
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-1,150,000
Closed -$38.3M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2020 Portfolio in Review

As of Q3 2020, Avidity Partners Management held 102 positions worth $2.16B, up 38% from $1.56B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Avidity Partners Management deployed $655M of net new capital in Q3 2020, opening 45 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 1,199,226 shares worth $94.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 92% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Exelixis, an estimated $44.9M trimmed.

  • Avidity Partners Management's largest Q3 2020 buy was Merck: 1,199,226 shares worth $94.9M.
  • Avidity Partners Management added most to Avantor in Q3 2020, an estimated $61.3M increase.
  • Avidity Partners Management's biggest Q3 2020 reduction was Exelixis, cutting an estimated $44.9M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q3 2020, selling an estimated $82.4M.
  • Avidity Partners Management's ten largest holdings make up 48% of its $2.16B portfolio in Q3 2020.
  • Avidity Partners Management opened 45 new positions and closed 34 in Q3 2020.
  • Avidity Partners Management's portfolio value rose 38% quarter-over-quarter to $2.16B.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.